Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin

Abstract

Among adults with LDL-C <130 mg/dl and high-sensitivity C-reactive protein ≥2 mg/l, rosuvastatin-allocated participants attaining LDL-C <50 mg/dl had a lower risk of cardiovascular events without a systematic increase in reported adverse events.

CKM Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia

“…Baseline features of the JUPITER population are described elsewhere. [24][25][26] Association With Baseline CK: GoDARTS and JUPITER CK levels were statistically significantly associated with the CKM Glu83Gly variant (n=4598, P value=2×10 −16 ) in the GoDARTS population. Carriers of the CKM variant CKM Glu83Gly, Creatine Kinase, and Myalgia (Glu83Gly:T/C) had mean CK of 86 (±68) compared with 126 (±82) for homozygotes of the common allele as seen in Table 2.…”

“…Only treatment-emergent adverse events were reported. 26 Myalgia was observed in 837 trial participants and was reported by Hsia et al 26 to be independent of their assigned therapy.…”

Effect of Low Cholesterol on Steroid Hormones and Vitamin E Levels

“…Similarly, in the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), among patients treated with rosuvastatin, attainment of LDL-C <50 mg/dL compared with LDL-C >50 mg/ dL was associated with a lower risk of cardiovascular events without significant differences in safety. 7 Ezetimibe, a nonstatin drug that decreases intestinal absorption of cholesterol, also lowers LDL-C. In a recent randomized trial of patients with acute coronary syndromes, a combination of ezetimibe and simvastatin resulted in low LDL-C levels (≈50 mg/dL) and reduced risk of subsequent cardiovascular events when compared with simvastatin monotherapy.…”

Less is More: Benefit of Achieving Very Low Low-Density Lipoprotein-Cholesterol Levels on Cardiovascular Events

“…4 Likewise, the Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial demonstrated a lower risk of ischemic events in patients with LDL-C <50 mg/dL vs. patients with LDL-C >50 mg/dL without any adverse effects. 5 Lately, the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT TIMI 40) trial further validated the concept that achieving very low LDL-C translates to favorable cardiac outcomes. IMPROVE-IT was a double-blind, randomized, placebo-controlled trial in which 18, 144 patients with acute coronary syndrome were treated with simvastatin and ezetimibe or simvastatin alone and followed for 7 years.…”